ANXA5 Antibody

1. AnxA5 2D-network mediates E-cadherin mobility in the plasmalemma that triggers human trophoblasts aggregation and thereby cell fusion. PMID: 28176826
2. Caspase-3 and -8 and annexin V may serve as diagnostic markers in Ovarian cancer , also explained that the decrement in control of the S phase in the cell cycle may considered one of the significant factors in the development of ovarian tumors PMID: 30197345
3. When ANXA5 expression increased, cell proliferation was inhibited by regulating the expression of bcl-2 and bax while cell metastasis was suppressed by regulating E-cadherin and MMP-9 expression. PMID: 30010106
4. Maternal carriers of the ANXA5 M2 haplotype has greater risk of developing placenta-mediated pregnancy complications, such as preeclampsia and intrauterine growth restriction. PMID: 29497952
5. The domain IV-truncated form of anxA5 is impaired in binding phosphatidylserine liposome and apoptotic cells, and anticoagulation activity. PMID: 29257055
6. increase in VEGF and Apelin, and decrease in Annexin A5 supports roles of hemo-dynamic alterations in fetoplacental circulation and structural alterations in uteroplacental bed occurring in preeclampsia. PMID: 29208172
7. In patients with colon cancer, annexin A5 expression in cancer tissues is related to lymph node metastasis and tumor grade. Serum level of annexin A5 is related to annexin A5 expression in cancer tissues. PMID: 29093625
8. annexin A5 anticoagulant has a role in adverse outcomes in antiphospholipid antibody positive patients with thrombosis or pregnancy complications PMID: 28393472
9. There was no significant difference in circulating ANXA5 levels between subjects of the non-pregnant, RPL and parous groups (median, 0.25 ng/ml vs. 0.21 ng/ml vs. 0.01 ng/ml, p = 0.14) (Fig. 1A ). Similarly, no significant differences in circulating ANXA5 levels were observed across these three clinical subgroups among M2-carriers or non-carriers, respectively. PMID: 28605660
10. Serum annexin A5 level was not altered in pre-eclampsia. PMID: 28501283
11. Annexin A5 was proposed to use in detection of apoptosis. associated with the Breast Cancer. Upregulation of the AA5 protein is detected in Pleomorphic Adenoma of the Parotid Gland. PMID: 28497265
12. Physiological function of ANXA5 as an embryonic anticoagulant that appears deficient in contiguous specter of thrombophilia-related pregnancy complications culminating more frequently in miscarriage in a maternal M2 carrier background. PMID: 28900802
13. This study confirmed the proposed role of M2/ANXA5 as embryonic, genetically associated thrombophilia predisposition factor for early recurrent pregnancy loss among ethnic Malay of Malaysia. PMID: 28108842
14. Circulating anxA5 levels are associated with carotid intima-media thickness but not coronary plaque composition in high-risk patients with diabetes mellitus. PMID: 28592134
15. Results showed that ANXA5 rs1050606 was significantly associated with left ventricular hypertrophy in Chinese endogenous hypertension patients. PMID: 29095261
16. Moreover, mechanism study exhibited that Annexin A5 could activate PI3K/Akt/mTOR signaling pathway, promote epithelial-mesenchymal transition (EMT) and the expression of MMP2 and MMP9. Annexin A5 may be a potential prognostic biomarker in RCC and promotes proliferation, migration and invasion of RCC cells via activating PI3K/Akt/mTOR signaling pathway and regulating EMT process and MMP expression. PMID: 28393205
17. human myotubes rendered deficient for Annexin-A5 (AnxA5) suffer from a severe defect in membrane resealing. PMID: 27286750
18. This study functionally characterized allelic variants in the ANXA5 promoter, both alone and in combinations, and the results suggest that combinations of several individual variants contribute to modulate the ANXA5 transcriptional activity, most likely through binding of nuclear factors. PMID: 27318245
19. Chronically increased alveolar annexin V levels, as reflected in increased idiopathic pulmonary fibrosis (IPF) BALF levels, may contribute to the progression of IPF by inducing the release of pro-fibrotic mediators. PMID: 26160872
20. lower exhaled breath condensate annexin A5 levels in children with exercise-induced asthma compared to non-exercised-induced one PMID: 25796304
21. The M2 haplotype is a risk factor for early spontaneous abortions, before the 12th week of gestation, and confers about the same relative risk to carriers of both sexes. PMID: 26371709
22. annexin A5 promoter haplotype M2 may not have a role in recurrent pregnancy loss in Estonia or Denmark PMID: 26135579
23. Annexin V is fused to an enzyme, creating a fusion protein that converts nontoxic drug precursors, prodrugs, into anticancer compounds while bound to the tumor, therefore mitigating the risk of side effects. PMID: 25899647
24. Neither the M1/M2 haplotypes nor the tag SNPs in ANXA5 were convincingly associated with pregnancy related venous thromboembolism. PMID: 25495894
25. Anx5 could protect cardiomyocytes adherens junctions and improve myocardial contractile function via regulation of p120 and anti-inflammation in LPS-induced endotoxemia. PMID: 25799159
26. The associated male partner risk confirms the proposed role of M2/ANXA5 as a genetic trait impeding embryonic anticoagulation. PMID: 25682309
27. AnxA5 promotes membrane resealing of injured human trophoblasts. PMID: 25595530
28. ANXA5 haplotypes/plasma ANXA5 levels were not associated with carotid IMT progression or cardiovascular disease risk in familial hypercholesterolemia patients. PMID: 25525746
29. The prognostic value of AnV and T cell apoptosis was evaluated in children with nephrotic syndrome in this review. PMID: 25661914
30. study found neither individual SNPs nor any of the four haplotypes within the ANXA5 gene upstream region were associated with deep venous thrombosis in the Dutch population PMID: 25382354
31. Lower incidence of M2/ANXA5 carriage in recurrent pregnancy loss patients with elevated lipoprotein(a) levels. PMID: 24335248
32. Polycystic ovary syndrome subjects showed increased annexin V positive microparticle concentrations compared with healthy volunteers. PMID: 25336711
33. Annexin A5 inhibits DLBCL cell invasion, MMP-9 expression/activity, and chemoresistance to CHOP through a PI3K-dependent mechanism. PMID: 25323007
34. Data show involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma PMID: 24743186
35. annexin A5 promotes GBM cell invasion, MMP-2 expression/activity, and chemoresistance to temozolomide through a PI3K-dependent mechanism. PMID: 25245332
36. Modified forms of LDL activate human T cells through dendritic cells. Annexin A5 inhibits these effects and promotes induction of regulatory T cells. PMID: 25395618
37. The annexin 5 in serums of pregnant women and patients with particular types of cancer PMID: 25080795
38. This review describes the structure, function and genetic expression of ANXA5, as well as its possible implication in recurrent pregnancy loss. PMID: 24152411
39. We could not prove any association of ANX5 antibodies and systemic lupus erythematosis. PMID: 24872142
40. genetic association studies in population in Japan: Data suggest that hypomorphic alleles in ANXA5 promoter in placenta (that is, fetal alleles), but not in maternal blood, contributes to onset of pre-eclampsia. PMID: 24140079
41. This study demonstrated the significant changes in AnxV levels and its function in type 1 diabetic patients. PMID: 24423325
42. Annexin A5 binds in a cooperative manner to to phosphatidylserine on apoptotic cell membranes. Shrunken apoptotic cells showed the highest Hill coefficient values. PMID: 24304966
43. frequency of annexin A5 (-1C/T) polymorphism was higher in systemic lupus erythematosus related groups but did not correlate with recurrent pregnancy loss (RPL) or annexin A5 level; anti-annexin A5 IgM level was higher among antiphospholipid syndrome patients and was associated with RPL PMID: 24600987
44. Annexin-V modified substrate was constructed via layer-by-layer (LBL) method for specific capture of early stage apoptotic Jurkat cells. PMID: 24021657
45. annexin A5 may play a crucial role in cisplatin-induced toxicity by mediating the mitochondrial apoptotic pathway via the induction and oligomerization of VDAC. PMID: 24318879
46. Suggest that annezin A5 IgG plays a significant role in producing a hypercoagulable state in primary and secondary antiphospholipid syndrome. PMID: 23981755
47. Variations within the ANXA5 gene upstream region were confirmed to be risk factors of recurrent pregnancy loss. PMID: 23850300
48. rs11575945 polymorphism of the annexin-A5 gene is associated with schizophrenia, and its minor allele is responsible for higher levels of the annexin-A5 protein in the blood and represent one of the risk factors for this disease PMID: 24466757
49. ANXA5 M2 haplotpye appears as an recurrent pregnany loss risk factor in male and female carriers with most distinguishable effects between the 10th and 15th week of gestation. PMID: 23899942
50. It appears that the haplotype M2/ANXA5 is not associated with the presence of anti-trophoblast antibodies. PMID: 23529182

Show More

Hide All

HGNC: 543

OMIM: 131230

KEGG: hsa:308

STRING: 9606.ENSP00000296511

UniGene: Hs.480653